4Q 2017 Results and preliminary annual report | Gentian
medical, diagnostics, immunoassays, assays, in vitro diagnostics, IVD products, avian antibodies, antibodies, clinical chemistry, diagnostic tests, biotechnology
post-template-default,single,single-post,postid-16448,single-format-standard,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-14.2,qode-theme-bridge,wpb-js-composer js-comp-ver-6.0.5,vc_responsive

4Q 2017 Results and preliminary annual report

4Q 2017 Results and preliminary annual report

Moss, 27 February 2018

Gentian Diagnostics AS announces its results for the 4th quarter and 2017 preliminary annual results. The highlights include:

  • 11% growth in sales revenue compared to 4Q16, 14 % y/y despite loss of our largest distributor
  • Increase in sales of fCAL turbo continues
  • Favorable development for Cystatin C in China


Please find the report enclosed.

The report will also be made available on www.gentian.com.

For further information, please contact:

Bård Sundrehagen CEO, Gentian Diagnostics
E-mail: bard.sundrehagen@gentian.no
Cell Phone: +47 924 14 117

Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

MeldingsID: 445248